Insider Transactions in Q2 2025 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
36,666
+17.13%
|
-
|
|
Jun 30
2025
|
Robert Renninger SVP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
12,359
+9.93%
|
-
|
|
Jun 30
2025
|
Mark Worthington General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,666
+23.34%
|
-
|
|
Jun 30
2025
|
Martin Javier San CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
46,666
+36.13%
|
-
|
|
Jun 30
2025
|
Mark James Litton President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,334
+23.59%
|
-
|
|
May 19
2025
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+6.63%
|
$0
$0.23 P/Share
|
|
May 19
2025
|
Robert Renninger SVP, Finance and Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.11%
|
$0
$0.23 P/Share
|